Nonalcoholic fatty liver disease: another leap forward

Nat Rev Gastroenterol Hepatol. 2021 Feb;18(2):85-86. doi: 10.1038/s41575-020-00406-0.


In 2020, there have been substantial advances in nonalcoholic fatty liver disease mechanisms, diagnostics and treatment. Key developments include the identification of a cellular and tissue signature to provide new insights into pathophysiology, advancements in non-invasive diagnostics and publication of interim results of the first phase III trial to demonstrate improvement in hepatic fibrosis.

Publication types

  • Review

MeSH terms

  • Chenodeoxycholic Acid / analogs & derivatives
  • Chenodeoxycholic Acid / therapeutic use
  • Disease Progression
  • Gastrointestinal Agents / therapeutic use
  • Humans
  • Imaging, Three-Dimensional
  • Liver / diagnostic imaging*
  • Liver / pathology
  • Machine Learning
  • Non-alcoholic Fatty Liver Disease / diagnostic imaging
  • Non-alcoholic Fatty Liver Disease / drug therapy*
  • Non-alcoholic Fatty Liver Disease / metabolism
  • Non-alcoholic Fatty Liver Disease / physiopathology


  • Gastrointestinal Agents
  • obeticholic acid
  • Chenodeoxycholic Acid